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A study of oropharyngeal candidiasis (OPC) in Indian human immunodeficiency virus (HIV)/AIDS patients
was conducted over a period of 15 months. This study revealed that 75% of the HIV/AIDS patients had OPC.
MIC testing revealed that 5% of the Candida isolates were fluconazole resistant. A correlation between
CD4-T-cell counts and development of OPC in HIV/AIDS patients was also observed. Molecular typing of C.
albicans isolates showed that all were genetically unrelated.
Oropharyngeal candidiasis (OPC) was at the top of the list
of opportunistic infections in Indian human immunodeficiency
virus (HIV)/AIDS patients before the era of highly active an-
tiretroviral therapy (1, 20, 27, 33). Although the incidences of
opportunistic infection have been reduced around the globe by
highly active antiretroviral therapy, the situation remains the
same in most developing countries, including India, where
patients can hardly afford this treatment. World Health Orga-
nization predictions have put India as one of the biggest re-
positories of HIV/AIDS patients in the coming decades (38,
39). In order to get an insight into the present scenario of OPC
in an Indian hospital, in the present prospective study, an
attempt was made to characterize the Candida species isolated
from OPC over a period of 15 months in HIV/AIDS patients,
mainly to know (i) the spectrum of isolates and (ii) its in vitro
pattern of susceptibility to fluconazole (FLC), a common an-
tifungal used for prophylaxis and treatment of OPC. In addi-
tion, the genetic relatedness of the isolates was also investi-
gated to get some idea about the primary source of infection.
All of the isolates included in this study were collected from
125 randomly selected HIV/AIDS patients. Whereas 100 pa-
tients showed clinical signs of OPC, 25 patients reported dis-
comfort or pain during chewing. All of them were attending
the clinic as outpatients of the All India Institute of Medical
Sciences, New Delhi, India, from December 1999 to March
2001. These patients were attending the clinic for the first time
and had no history of prior treatment with antifungal and
antiretroviral drugs. Samples were collected with two sterile
cotton swabs. One swab was used to detect the presence of any
yeast by Gram staining, and the other was used to test growth
on Sabouraud dextrose agar slants containing 2 g of genta-
micin per ml and 0.5% cycloheximide. In the case of positive
growth, yeast identification was done by conventional methods.
The method used was the germ tube production test, which was
done by inoculation of a single colony into 0.5 ml of horse
serum, followed by incubation at 37°C for 2 h. Morphology
testing for the presence of chlamydospores, pseudohyphae,
true mycelium, and blastospore arrangement was done on corn
meal agar. An enzymatic triphenyl tetrazolium chloride reduc-
tion test was performed in which each Candida species grows
with a distinct texture and color. For further characterization,
each isolate was subjected to carbohydrate assimilation and
fermentation tests (2, 3). To differentiate Candida albicans
from C. dubliniensis, all C. albicans isolates (confirmed by con-
ventional methods) were subjected to growth at 45°C and a
Tween 80 opacity test (13, 31). Out of 100 samples, 75 were
found to be positive for Candida species infection by direct
microscopy and culture. This value (75% positive) is lower
than that reported (90%) in western populations (5, 10, 23, 35),
and one can speculate that the Candida carriage rate in the
Indian population is probably lower. Species identification re-
vealed that C. albicans (86%) was the most predominant spe-
cies; as reported earlier (20), a small percentage of other spe-
cies has also been identified, i.e., C. parapsilosis (8%) and C.
glabrata and C. krusei (3%). The most interesting fact is that C.
tropicalis and C. dubliniensis were not isolated. This is a sur-
prising observation in view of reports from developed coun-
tries, where non-C. albicans candidiasis is a major problem in
HIV/AIDS patients (9, 11, 12, 18, 19). Antifungal drug pro-
phylaxis is rarely practiced in India, and this may be the reason
for this observation. Currently, the most widely used drug for
treating candidiasis is FLC (16, 17, 24, 28, 36). In vitro FLC
susceptibility testing of all of the isolates was done by microdi-
lution susceptibility assay (22). More than 93% of the Candida
isolates were found to be susceptible, with MICs of 8 g/ml;
2% were found to be dose-dependently susceptible, with MICs
of 16 to 32 g/ml; and only 5% (two isolates of C. albicans and
one each of C. glabrata and C. krusei) were found to be resis-
tant, with MICs of 64 g/ml. The resistant strains (5%) were
from patients who never took FLC. These resistant isolates can
be described as primarily or intrinsically resistant strains. It is
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not clear why FLC resistance was low in Candida species iso-
lated from these patients. A couple of years ago, it could have
been explained on the basis of the nonaffordability of expen-
sive drugs like FLC, which was not in use as a routine prophy-
lactic antifungal drug. However, over the years the situation
has changed. Now, increasing numbers of patients are getting
treatment by FLC. Factors contributing to FLC resistance are
numerous and include the degree of immunosuppression of
the patient, the degree of prior exposure to FLC, the contri-
bution of other chemotherapeutic drugs, and the intrinsic re-
sistance of Candida species (8, 37). However, this is only one-
time testing; the study should be continued with repeated
collection of isolates from the same patients at different time
intervals.
There has been a rapid growth in interest in assessing the
genetic relatedness of isolates of the same species in recent
years, especially for epidemiology (32). However, no serious
attempt has been made so far to detect the source of primary
infection and genetic relatedness of the strains isolated in
Indian hospitals. To assess the genetic relatedness of C. albi-
cans isolates obtained from HIV/AIDS patients with OPC, we
used Southern blot hybridization with the moderately repeti-
tive, C. albicans-specific DNA fragment CARE-2 (14, 15, 29,
32). To accomplish this, we hybridized the EcoRI-digested
genomic DNAs of all of the Candida isolates obtained from
OPC-positive patients with the labeled probe CARE-2 (7, 30).
The CARE-2 hybridization patterns of these isolates were
found to be relatively complex (Fig. 1). However, it was ap-
parent from the hybridization patterns that each fingerprinted
isolate was different. When these patterns were analyzed quan-
titatively with the Dendron software package (version 3.0; Soll-
tech, Iowa City, Iowa) as described by Pujol et al. (26), it was
further confirmed that all of the C. albicans isolates were
different and genetically unrelated (data not shown). The total
unrelatedness of the isolates indicates different sources of in-
fection. Since we do not have any knowledge about the com-
mensal status of the outpatients surveyed, it is not possible to
speculate about the primary source of infection. The possibility
of a commensal organism becoming a pathogen, however, can-
not be ruled out totally.
The relationship between CD4-T-cell counts and the onset
of OPC in HIV/AIDS patients has been observed in several
western reports (4–6, 17, 21, 25, 34). However, such observa-
tions are lacking in Indian hospitals. In order to correlate
CD4-T-cell counts and OPC in a selected number of patients
(n  100), CD4-T-cell counts were determined with a
Coulter Manual CD4-T-cell count kit (Coulter Corporation,
Miami, Fla.). Of the 100 patients tested, 75 had clinically ob-
servable OPC (confirmed by microbiological methods) and 25
patients did not have any clinical lesions. On the basis of the
severity of the OPC clinical lesions versus CD4-T-cell counts,
the patients included in this study could be classified into three
broad categories. In the first category, the range of CD4-T-
cell counts was 42 to 100 cells/l, which was observed among
20 patients with severe OPC lesions (a very thick, curdy mem-
brane spreading over the tongue and oropharynx). The second
category had CD4-T-cell counts ranging from 125 to 200
cells/l, which were observed among 39 patients having mod-
erate OPC lesions (a membrane on the tongue and stomatitis).
The third category had CD4-T-cell counts ranging from 201
to 245 cells/l, which were observed among 16 patients with
mild OPC lesions (no membrane but stomatitis or gingivitis).
In 25 patients having CD4-T-cell counts in the range of 325 to
626 cells/l (mean, 424 cells/l), no such lesions were detected.
In India, antiretroviral therapy is prescribed on the basis of
CD4-T-cell counts. CD4-T-cell counting is expensive, and
FIG. 1. DNA fingerprinting patterns of all of the Candida strains obtained from HIV/AIDS patients with OPC. The numbers at the top are
isolate numbers. Lanes: M, molecular size marker (1-kb ladder; New England Biolabs); C, control C. albicans strain ATCC 10261; 8, 9, 11, 12, 37,
44, 56, 59, 70, and 74, non-C. albicans Candida strains (no hybridization or nontypical hybridization with the CARE-2 probe); all others, C. albicans
isolates (a total of 65 isolates).
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the necessary equipment is available in only a few selected
institutions. This study suggests that the severity of OPC de-
tected clinically can provide a rough estimate of CD4-T-cell
counts, depending on which antiretroviral therapy can be in-
stituted if needed. Finally, this study is probably the first ever
survey of OPC in HIV/AIDS patients in India in which com-
prehensive laboratory data were generated; this will help not
only in patient management but also in future clinical research.
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